Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of 177Lu-JH020002 in advanced prostate cancer
CTR20233508Phase 2Active
- Sponsor
- Bivision Pharmaceuticals
- Start
- Dec 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu-177 JH020002 in prostate adenocarcinoma, sponsored by Bivision Pharmaceuticals. Started Dec 2023; status: active.
02
Drugs
lutetium Lu-177 JH020002
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on CTR20233508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233508.